Multi-level marketing company Herbalife Nutrition Ltd will pay $123.1 million to settle criminal and civil charges for bribing Chinese officials in government agencies and media outlets from 2007 to 2016.
Herbalife will pay $55.74 million in criminal fine, and $67.31 million in disgorgement and interest in a related civil case under the US Securities and Exchange Commission.
According to Acting US Attorney Audrey Strauss, Herbalife approved “extensive and systematic corrupt payments” to Chinese officials, while falsifying records to make its bribes appear as legitimate business expenses.
The company allegedly gave cash, and perks on entertainment, meals, and travel to obtain direct selling licenses, reduce government scrutiny, and suppress negative coverage by state-controlled media.
US Department of Justice said that Herbalife Nutrition entered a three-year deferred prosecution agreement where it admitted conspiring to violate the books and records provision of the anti-bribery law Foreign Corrupt Practices Act.
The multi-level marketing company's products include dietary supplements.
China accounted for 19 percent of Herbalife’s $4.49 billion of net sales in 2016, up from 7 percent in 2006.


BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Standard Chartered Expands Hedge Fund Access for Wealth Clients
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 



